The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | What is the role of autologous transplant in newly diagnosed multiple myeloma today?
In this interview, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, discusses the role of autologous stem cell transplantation (autoSCT) in newly diagnosed multiple myeloma (MM) in the current era, highlighting the need to weigh up the benefits against the risk of side effects for eligible patients. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I chaired a debate around the use of autologous stem cell transplant in newly diagnosed myeloma patients who would be considered eligible for this treatment and whether for patients who are considered eligible it should be considered for all of those patients or whether there are some patients who perhaps don’t need to undergo an autologous stem cell transplant...
I chaired a debate around the use of autologous stem cell transplant in newly diagnosed myeloma patients who would be considered eligible for this treatment and whether for patients who are considered eligible it should be considered for all of those patients or whether there are some patients who perhaps don’t need to undergo an autologous stem cell transplant. And it was a wide-ranging debate looking at lots of different pieces of data and we are starting to learn more about which patients might benefit the most from an autologous stem cell transplant and which patients we might think about considering not going ahead with transplant. I think overall the feeling of the speakers and myself as chair is that probably an autologous stem cell transplant is considered a good treatment option for patients who are eligible, but this needs to be carefully weighed against the risks of side effects for patients. And we hope that going forward, we will learn more. For example, in patients who have perhaps high-risk features to their disease, I think we would be very reluctant to stop going ahead with a transplant. But for patients who are perhaps achieving very deep responses or MRD negative responses after induction, that’s a situation when we might consider more the nuances of who would be most appropriate to go ahead with a transplant. And hopefully as we move forward, we’ll learn more about which patients should go ahead or not go ahead with a transplant in the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
